// App-Quantinova.ai

892 : Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream inputs from mTOR

Researchers

Presenter

  • Gnana P. Krishnamoorthy

Principal Investigators

  • Inigo Landa

  • Jeffrey A. Knauf

  • James Nagarajah

  • Gunnar Ratsch

  • Hans-Guido Wendel

  • James A. Fagin

Medical Centers

  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

  • Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Thyroid Cancer

  • Melanoma

  • Solid malignancies

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphorylated 4E-binding protein 1

  • Plasmin-alpha2-plasmin inhibitor complex

  • Fractalkine

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved